A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)
Fenebrutinib, an oral BTK inhibitor, shows non-inferiority to ocrelizumab in PPMS, targeting CNS inflammation, reducing infusion burden, and expanding equitable, scalable progressive multiple sclerosis care.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.